Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven?
作者信息
Maan Raoel, van der Meer Adriaan J
机构信息
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
出版信息
Hepatobiliary Surg Nutr. 2020 Apr;9(2):257-259. doi: 10.21037/hbsn.2019.10.04.
Abstract
摘要
相似文献
1
Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven?慢性丙型肝炎病毒感染患者直接抗病毒治疗的结果：临床益处得到证实了吗？
Hepatobiliary Surg Nutr. 2020 Apr;9(2):257-259. doi: 10.21037/hbsn.2019.10.04.
2
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.美国丙型肝炎病毒感染全口服直接抗病毒药物的初始吸收率、治疗时间和真实世界疗效：一项回顾性队列分析。
PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
3
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
4
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.终末期肾病患者使用丙型肝炎病毒直接抗病毒药物的“真实世界”经验。
Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.
5
Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.埃及慢性丙型肝炎病毒感染患者直接抗病毒药物治疗前后的男性性功能障碍。
J Sex Med. 2019 Mar;16(3):402-409. doi: 10.1016/j.jsxm.2019.01.309.
6
[Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].直接作用抗病毒药物治疗慢性丙型肝炎病毒感染患者的有效性和安全性
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):175-178. doi: 10.3760/cma.j.issn.1007-3418.2018.03.004.
7
Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.肝移植受者中丙型肝炎病毒直接作用抗病毒药物的移植前与移植后治疗：更多待解决的问题
Exp Clin Transplant. 2017 Feb;15(Suppl 1):1-5. doi: 10.6002/ect.mesot2016.L19.
8
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.直接作用抗病毒药物治疗丙型肝炎期间乙型肝炎病毒再激活：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180. doi: 10.1016/S2468-1253(18)30002-5. Epub 2018 Jan 19.
9
Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.直接作用抗病毒药物治疗慢性丙型肝炎患者 TRIM22 mRNA 的表达。
APMIS. 2020 Apr;128(4):326-334. doi: 10.1111/apm.13024. Epub 2020 Jan 28.
10
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
引用本文的文献
1
Hepatitis C virus: A critical approach to who really needs treatment.丙型肝炎病毒：关于真正需要治疗人群的关键探讨。
World J Hepatol. 2022 Jan 27;14(1):1-44. doi: 10.4254/wjh.v14.i1.1.
本文引用的文献
1
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
2
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化患者肝细胞癌的发生率。
Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.
3
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.丙型肝炎肝硬化患者持续病毒应答者发生肝细胞癌的风险：治疗方案的作用。
J Hepatol. 2018 Apr;68(4):646-654. doi: 10.1016/j.jhep.2017.10.033. Epub 2017 Nov 16.
4
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.帕利瑞韦/利托那韦/奥比他韦/达沙布韦与来迪派韦索磷布韦方案对生存的影响与未治疗的丙型肝炎病毒感染者相比：来自 ERCHIVES 的结果。
Clin Infect Dis. 2017 Sep 15;65(6):1006-1011. doi: 10.1093/cid/cix364.
5
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.直接作用抗病毒药物治疗慢性丙型肝炎病毒感染合并肝硬化患者的安全性和有效性。
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1821-1830.e6. doi: 10.1016/j.cgh.2016.07.001. Epub 2016 Jul 9.
6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
7
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.慢性丙型肝炎合并晚期肝纤维化患者持续病毒学应答与全因死亡率的关系。
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
Zotero 插件